GlobeNewswire Inc | Dec 2, 2021 07:00AM EST

December 02, 2021

NEW YORK and SALT LAKE CITY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release first quarter fiscal year 2022 financial results on Tuesday, December 7, 2021, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (EST) / 1:30 p.m. (GMT).

Conference Call Details:US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551US/Canada Participant International Dial-In Number: (914) 987-7290United Kingdom International Dial-In Number: 0800 0288 438United Kingdom Local Dial-In Number: 0203 1070 289Conference ID: 2495524

Webcast Registration link: https://edge.media-server.com/mmc/p/2s8cwr7x

For further information, please contact:

Renalytix plc www.renalytix.comJames McCullough, CEO Via Walbrook PR Stifel (Nominated Adviser, Joint Tel: 020 7710 7600Broker)Alex Price / Nicholas Moore Investec Bank plc (Joint Broker) Tel: 020 7597 4000Gary Clarence / Daniel Adams Walbrook PRLimited Tel: 020 7933 8780 or renalytix@walbrookpr.comPaul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303 CapComm Partners Peter DeNardo Tel: 415-389-6400 or investors@renalytix.com

About RenalytixRenalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosisfor kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Companys lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visitwww.kidneyintelx.com). For more information, visitwww.renalytix.com.